Page Banner
Mayo Clinic Laboratories > Neurology

PUSHING THE BOUNDARIES OF NEUROLOGY DIAGNOSIS

Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.

Eye on Innovation Phenotype-specific approach transcends traditional testing for autoimmune neurological conditions
Diagnostics in Practice Multiple sclerosis: Diagnostic criteria update and kappa free light chain testing
Microlearning Autoimmune Encephalitis Misdiagnosis
Patient Spotlight A Mayo Pathologist’s Journey through Paraneoplastic Syndrome and a Double Lung Transplant: Dr. Brad Karon
Webinar Pediatric Autoimmune Neurologic Disorders

NEUROLOGY TEST SPECIALTIES

Autoimmune disorders Autoimmune disorders
Autoimmune disorders

Covering the spectrum of autoimmune neurological disorders, our evaluations apply a phenotype-specific approach to diagnose and guide treatment for patients affected by immune-mediated neurological illness.

Biopharma testing Biopharma testing
Biopharma testing

With 19 subspecialty labs that perform neurology testing, we are at the forefront of research that integrates novel biomarker discoveries into our evaluations. Our menu, including testing for Alzheimer’s disease, dementia, and autoimmune conditions, provides partners with results that move solutions through the development pipeline.

Demyelinating disease Demyelinating disease
demyelinating disease

We offer sensitive and specific testing to diagnose a range of demyelinating diseases, from classic multiple sclerosis (MS) to atypical MS, AQP4/MOG-associated disorders, and spinal cord disorders.

Dementia Dementia
Dementia

Offering the industry’s most sophisticated suite of testing available, including biomarker evaluations, autoimmune panels, testing for rapidly progressive cases, and an innovative combination assay, Mayo Clinic Laboratories is a one-stop laboratory solution for dementia and Alzheimer’s disease testing.

Epilepsy Epilepsy
Epilepsy

We offer testing that identifies genetic and autoimmune causes of epilepsy. With testing developed by neurologists, epileptologists, and geneticists, physicians can determine the causes of epilepsy in their patients and identify potential treatment options.

Movement disorders Movement disorders
Movement disorders

Our comprehensive movement disorder testing includes an autoimmune movement disorders panel that contains the latest newly discovered clinically actionable antibodies. We also offer hereditary movement disorders testing that covers ataxia, Huntington's disease, Parkinson's disease, and more.  

Neurogenetics Neurogenetics
Neurogenetics

A multidisciplinary team of clinical neurology experts, laboratory scientists, and genetic counselors work collaboratively to develop and implement our neurogenetic testing. Covering the full range of neurogenetic illness, our testing is unparalleled in scope and detail and uses an algorithmic and phenotypic approach that ensures the right patient receives the right test at the right time.

Neuromuscular disorders Neuromuscular disorders
Neuromuscular disorders

Our comprehensive menu of precision testing enables physicians to diagnose and manage patients with disorders such as myasthenia gravis, Lambert-Eaton syndrome, immune-mediated necrotizing myopathy, hereditary myopathy, and more.

Pediatrics Pediatrics
Pediatrics

Including evaluations for autoimmune central nervous system disorders, multiple sclerosis, and narcolepsy, our data-driven pediatric testing provides precision results to guide treatment and place young patients on the path to healing.

Peripheral neuropathy Peripheral neuropathy
Peripheral neuropathy

We offer testing to identify peripheral autoimmune neuropathy with axonal or demyelinating causes, as well as next-generation sequencing to help establish whether a peripheral neuropathy is genetic in nature.

“The ability of Mayo Clinic to make discoveries and translate these into solutions for our patients is critical to our mission.”

John Mills, Ph.D., co-director, Neuroimmunology Laboratory

OUR DIFFERENCE

Clinically driven neurology test menu
Consolidate more of your sendout testing to one trusted lab.

Solving the most complex neurologic cases
We continually innovate to develop new testing approaches that enable answers to the rarest and most complex neurological conditions.

Backed by the world’s leading experts
Our laboratories are led by clinical neurologists who have extensive experience using testing to guide and directly impact patient care. These experts interpret each evaluation, providing clinically actionable answers, not just results.

News and updates

The latest

Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing featured image
Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing

Join Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.

Learn more
Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2 blood biomarker testing

Join Mayo Clinic Laboratories and C2N Diagnostics for our webinar exploring how the evolution of blood biomarker testing for Alzheimer's disease has expanded access to earlier, less-invasive diagnosis. Focusing on the newly FDA-cleared PrecivityAD2 blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how results from blood biomarker testing can support timely diagnosis, informed clinical decision-making, and improved patient care.

Comprehensive autoimmune/ paraneoplastic evaluations are critical in identifying coexisting antibodies

Find out how our autoimmune/paraneoplastic encephalopathy evaluations can identify multiple antibodies and guide the search for occult cancer.

UNC Health: Reducing redundant testing and achieving improved answers

Collaborating with Mayo Clinic Laboratories, UNC Health streamlined neuroimmunology test ordering — eliminating outmoded testing and elevating diagnostic accuracy.

Unlock the Full Potential of Research Data

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss advancement in Alzheimer’s testing and practical uses of artificial intelligence (AI) in healthcare. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories’ chief digital innovation officer, to explore the evolving role of data in research and development.

Nerve biopsy testing

Learn more about how Mayo Clinic’s Nerve Pathology Laboratory leverages decades of nerve pathology testing experience and unmatched clinical expertise to provide diagnostic clarity for rare and complex neuropathies.

PDE10A autoimmunity presents as hyperkinetic movement disorder triggered by ICI treatment

Find out how our suite of autoimmune movement disorder testing can help diagnose PDE10A autoimmunity in patients who present with hyperkinetic movement disorders.

Genome-wide methylation profiling brings new clarity to brain tumor diagnosis

Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.

The Role of GFAP and Its Clinical Use Cases

Recording coming soon. Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.

Muscle biopsy testing

Discover how Mayo Clinic’s nationally recognized Muscle Pathology Laboratory provides unparalleled diagnostic accuracy for rare muscle diseases through decades of experience, specialized testing, and integrated clinical-pathological evaluation.

Living with ultra-rare epilepsy and chasing her dream: Giana Urse

Supported by Mayo Clinic’s holistic, precision medicine approach, which included advanced genetic insights, access to an emerging therapy, and tailored treatment monitoring, Giana Urse gained the confidence and clarity she needed to pursue her dream of becoming a dog trainer.

Using CSF testing to confirm autoimmune GFAP meningoencephalomyelitis

Learn how our autoimmune/paraneoplastic evaluation for encephalopathy uses CSF testing to confirm an autoimmune GFAP meningoencephalomyelitis diagnosis.

Autoimmune Encephalitis Misdiagnosis

Autoimmune encephalitis (AE) is a rare but serious condition, and accurate diagnosis is critical. Misdiagnosis can lead to unnecessary treatments, delayed care, and preventable complications.

View More
Resources
Download Neurology test request form
Delivering specialized testing and consultative support for:
Learn more Commercial laboratories
Learn more Global healthcare
Learn more Hospitals and health systems

LEARN MORE ABOUT HOW WE CAN BUILD YOUR LAB'S POTENTIAL.

(BETA) Choose a language to view this content in:
About the translation.